1009303-44-9

Basic information

• Product Name: (3S,3'S)-4,4'-(7-chloropyrido[2,3-d]pyriMidine-2,4-diyl)bis(3-MethylMorpholine)
• Synonyms: (3S,3'S)-4,4'-(7-chloropyrido[2,3-d]pyriMidine-2,4-diyl)bis(3-MethylMorpholine);7-Chloro-4-((S)-3-methylmorpholin-4-yl)-2-((S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidine
• CAS NO: 1009303-44-9
• Molecular Formula: C₁₇H₂₂ClN₅O₂
• Molecular Weight: 363.84188
• Mol File: 1009303-44-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 567.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.291±0.06 g/cm3(Predicted)
• PKA: 5.00±0.30(Predicted)
• CAS DataBase Reference: (3S,3'S)-4,4'-(7-chloropyrido[2,3-d]pyriMidine-2,4-diyl)bis(3-MethylMorpholine)(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,3'S)-4,4'-(7-chloropyrido[2,3-d]pyriMidine-2,4-diyl)bis(3-MethylMorpholine)(1009303-44-9)
• EPA Substance Registry System: (3S,3'S)-4,4'-(7-chloropyrido[2,3-d]pyriMidine-2,4-diyl)bis(3-MethylMorpholine)(1009303-44-9)

Safety Data

• Hazardous Substances Data: 1009303-44-9(Hazardous Substances Data)

Usage

General Description

The chemical compound (3S,3'S)-4,4'-(7-chloropyrido[2,3- d]pyriMidine-2,4-diyl)bis(3-MethylMorpholine) is a bis-morpholine compound with a 7-chloropyrido[2,3-d]pyriMidine-2,4-diyl central core. (3S,3'S)-4,4'-(7-chloropyrido[2,3-d]pyriMidine-2,4-diyl)bis(3-MethylMorpholine) consists of two 3-methylmorpholine moieties connected by the central pyrido[2,3-d]pyriMidine ring. It is a white crystalline solid with a molecular formula of C17H24ClN5O2 and a molecular weight of 367.85 g/mol. The compound has potential applications in pharmaceuticals, agrochemicals, and other industries due to its unique structure and potential biological activities. Its specific uses and properties would depend on further research and development.

Upstream product

• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 
• 938443-19-7 7-chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 938443-20-0 2,4,7-trichloropyrido[2,3-d]pyrimidine 
• 58584-92-2 2-amino-6-chloronicotinic acid 
• 350595-57-2 (S)-3-methylmorpholine 
• 1009303-42-7 (S)-4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)-3-methylmorpholine 

Downstream Products

• 1009298-09-2 AZD₈₀₅₅ 
• 1009298-78-5 C₂₄H₂₈FN₅O₃ 
• 1009303-64-3 4-[2,4-bis-((S)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-benzoic acid methyl ester 
• 1009303-63-2 4-[2,4-bis-((S)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-fluoro-benzonitrile 

Relevant articles and documents

METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS

The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).